AbCellera Biologics (ABCL) Current Assets (2020 - 2026)

AbCellera Biologics has reported Current Assets for 7 years, with the latest figure at $664.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 13.12% year-over-year to $664.6 million; the trailing twelve-month figure through Mar 2026 stood at $664.6 million (down 13.12% YoY), and the FY2025 full-year result was $728.2 million, down 3.08% from the prior year.
• Current Assets for Q1 2026 stood at $664.6 million, down from $728.2 million in the prior quarter.
• The five-year high for Current Assets was $1.2 billion in Q1 2022, with the low at $664.6 million in Q1 2026.
• Historically, Current Assets has averaged $866.3 million across 5 years, with a median of $813.9 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets soared 32.4% — and 2023, when it declined 19.9%.
• AbCellera Biologics' Current Assets stood at $1.0 billion in 2022, then dropped by 14.97% to $872.0 million in 2023, then slipped by 13.83% to $751.4 million in 2024, then dropped by 3.08% to $728.2 million in 2025, then declined by 8.74% to $664.6 million in 2026.
• The last three Current Assets figures came in at $664.6 million (Q1 2026), $728.2 million (Q4 2025), and $695.1 million (Q3 2025), per Business Quant data.